MX2019008535A - Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. - Google Patents
Agonista del ppar gamma para el tratamiento de la enfermedad de huntington.Info
- Publication number
- MX2019008535A MX2019008535A MX2019008535A MX2019008535A MX2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A MX 2019008535 A MX2019008535 A MX 2019008535A
- Authority
- MX
- Mexico
- Prior art keywords
- pparï
- huntington
- disease
- treatment
- agonist
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019008535A true MX2019008535A (es) | 2019-12-02 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019008535A MX2019008535A (es) | 2017-01-18 | 2018-01-18 | Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (enExample) |
| EP (1) | EP3570841A4 (enExample) |
| JP (1) | JP2020505448A (enExample) |
| KR (1) | KR20190122664A (enExample) |
| CN (1) | CN110461330A (enExample) |
| AU (1) | AU2018210165A1 (enExample) |
| BR (1) | BR112019014529A2 (enExample) |
| CA (1) | CA3050104A1 (enExample) |
| EA (1) | EA201991716A1 (enExample) |
| IL (1) | IL268008A (enExample) |
| MX (1) | MX2019008535A (enExample) |
| SG (1) | SG11201906644YA (enExample) |
| WO (1) | WO2018136635A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| JP2008515978A (ja) * | 2004-10-13 | 2008-05-15 | ユニバーシティ オブ コネチカット | カンナビネルジック脂質リガンド |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| EP2448412B1 (en) * | 2009-07-01 | 2019-05-01 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
| AU2014364447A1 (en) * | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
-
2018
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018136635A1 (en) | 2018-07-26 |
| SG11201906644YA (en) | 2019-08-27 |
| AU2018210165A1 (en) | 2019-08-01 |
| KR20190122664A (ko) | 2019-10-30 |
| JP2020505448A (ja) | 2020-02-20 |
| EP3570841A1 (en) | 2019-11-27 |
| CA3050104A1 (en) | 2018-07-26 |
| IL268008A (en) | 2019-09-26 |
| US20190350918A1 (en) | 2019-11-21 |
| BR112019014529A2 (pt) | 2020-02-27 |
| EA201991716A1 (ru) | 2020-02-04 |
| CN110461330A (zh) | 2019-11-15 |
| EP3570841A4 (en) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| WO2018226622A8 (en) | Compounds for treating huntington's disease | |
| PH12015502788A1 (en) | Antibody formulations and methods | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| NZ763098A (en) | Thiazolopyridine derivatives as gpr119 agonists | |
| SG10201903823QA (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| MX2009009207A (es) | Metodos y composiciones para normalizar las secreciones de glandulas meibomianas. | |
| EA201591743A8 (ru) | СТИМУЛЯТОРЫ sGC | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| NZ763528A (en) | Heterocyclic gpr119 agonist compounds | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| CA3073829A1 (en) | Methods and compositions for detecting and treating endometriosis | |
| MX366765B (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| MX2020012800A (es) | Cannabinoides y usos de los mismos. | |
| MX2019001979A (es) | Agonista de ppar? para el tratamiento de neoplasias hematicas. | |
| MX2019011867A (es) | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. |